A painful dysfunction of the somatosensory nervous system in the body is called chemotherapy-induced peripheral neuropathy or CIPN. It is estimated that chemotherapy-induced peripheral neuropathy affects an estimate of 68.0% patients who undergo within their first month of diagnosis, among which 30% patients are affected on a chronic basis. The rising prevalence of chronic diseases is promoting the growth of Chemotherapy Treatment Market. According to Fortune Business Insights, the market for Chemotherapy Induced Peripheral Neuropathy Treatment is anticipated to rise exponentially with increasing prevalence of diabetes worldwide.
Strategic Partnerships to Help Market Players Gain Strong Foothold in Market
As per the report, the global Chemotherapy Treatment Market highlights some of the major market shareholders significantly driving the market. These companies are mentioned below:
Manufactures continue to focus on new product launches and merger and acquisition strategies to increase their customer base and broaden product portfolio. These manufacturers produce new therapeutic methods to maintain a strong foothold in the market. Some of the recent development made by companies are mentioned below:
2015 – At the 34th annual meeting of American Pain Society, preclinical results of tetrodotoxin were presented by WEX Pharmaceuticals Inc., for treating chemotherapy-induced peripheral neuropathy in May 2015.
2017 – A strategic partnership was agreed upon by Solasia and the Association of PledPharma for the development of PledOx in November 2017. PledOx is a potential drug that is used for
preventive treatment of chemotherapy-induced peripheral neuropathy in the market in Asia Pacific.
Some of the companies operating in the global Chemotherapy Induced Peripheral Neuropathy Treatment market include:
- Eurofins Advinus
- Solasia Pharma K.K.
- WEX Phamaceuticals, Inc.
- Asahi Kasei Corporation.
- ChromaDex, Inc.
- MediciNova, Inc.
- Apollo Endosurgery, Inc.
- RELIEF THERAPEUTICS Holding SA
- Hoffmann-La Roche Ltd.
- Midatech Pharma PLC
- Lee’s Pharmaceutical Holdings Limited
More Trending Topics From Fortune Business [email protected]
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.